PHARMAC to fund new treatment that will help prevent blindness

24 October 2017

In New Zealand, from November 1, 2017, Ozurdex (dexamethasone implants) will be funded for eligible people with diabetic macular edema (DMO), a serious complication of type 1 and type 2 diabetes that can cause blindness if untreated.

The dexamethasone implants, from Ireland-headquartered Allergan (NYSE: AGN), will be funded for people who have diabetic macular edema, have had cataract surgery and meet the other special authority criteria, says NZ’s Pharmaceutical Management Agency PHARMAC.

PHARMAC director of operations Sarah Fitt says the new treatment is a significant advance in the way diabetic macular oedema is treated for those who meet the criteria.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK